Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study-Reference-Cited by-同舟云学术

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

Published:2007-08 Issue:9585 Volume:370 Page:389-397
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Kappos Ludwig,Freedman Mark S,Polman Chris H,Edan Gilles,Hartung Hans-Peter,Miller David H,Montalbán Xavier,Barkhof Frederik,Radü Ernst-Wilhelm,Bauer Lars,Dahms Susanne,Lanius Vivian,Pohl Christoph,Sandbrink Rupert

Publisher

Elsevier BV

Subject

General Medicine

Reference24 articles.

1. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group;Jacobs;N Engl J Med,2000

2. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study;Comi;Lancet,2001

3. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes;Kappos;Neurology,2006

4. New diagnostic criteria for multiple sclerosis: guidelines for research protocols;Poser;Ann Neurol,1983

5. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time;Kuhlmann;Brain,2002

Cited by 442 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interpretable Machine Learning for Predicting Multiple Sclerosis Conversion from Clinically Isolated Syndrome;2024-07-19

2. Clinicoradiological Factors for Predicting and Monitoring the Progression of Multiple Sclerosis;Journal of Multiple Sclerosis and Neuroimmunology;2024-06-30

3. Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial;Journal of Neurology;2024-05-10

4. Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies;Therapeutic Advances in Neurological Disorders;2024-01

5. Pediatric Multiple Sclerosis: Clinical Presentation, Diagnosis and Management;Reference Module in Neuroscience and Biobehavioral Psychology;2024